Login / Register

Oxford Peptide Labs-Logo
SHIPPED STRAIGHT FROM OUR FREEZER
24 MONTH SHELF LIFE
HPLC TESTED 99%+ PURITY
SHIPPED WITHIN 24 HOURS
CJC-1295 (No DAC) / Modified GRF 1-29
VIAL0001
Box-01
Test HPLC
OVER 80K+
CJC-1295 (No DAC) / Modified GRF 1-29
VIAL0001
Box-01
Test HPLC
OVER 80K+

CJC-1295 (No DAC)

£25.90

In stock
High-purity Modified GRF 1-29 (CJC-1295 No DAC) lyophilized powder for research into pulsatile growth hormone secretion and sleep physiology.

Description

CJC-1295 (No DAC), commonly referred to scientifically as Modified GRF 1-29, is a tetrasubstituted analogue of Growth Hormone-Releasing Hormone (GHRH). Unlike its “With DAC” counterpart, this peptide lacks the Drug Affinity Complex, resulting in a significantly shorter half-life (approximately 30 minutes) that mimics the body’s natural pulsatile release of growth hormone. This modification improves resistance to enzymatic cleavage by DPP-IV, making it a highly effective tool for researching physiological growth hormone secretion patterns without the continuous stimulation associated with long-acting analogues.

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 (No DAC)”

Your email address will not be published. Required fields are marked *

No more offers for this product!

General Inquiries

There are no inquiries yet.

Category Tags , , Brand:
  • Download COA here:
Download COA (PDF)

Please note if you have a different Batch ID please contact us for the latest COA.

Chemical Specifications:

  • Chemical Name: Tetrasubstituted Growth Hormone-Releasing Hormone (1-29)

  • Synonyms: Mod GRF 1-29, CJC-1295 No DAC, NC-26-0161

  • CAS Number: 863288-34-0 (base sequence)

  • Molecular Formula: C152H252N44O42

  • Molecular Weight: 3367.97 g/mol

  • Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

  • Structure: 29-amino acid peptide with substitutions at positions 2, 8, 15, and 27

Description & Mechanism
CJC-1295 (No DAC), commonly referred to scientifically as Modified GRF 1-29, is a tetrasubstituted analogue of Growth Hormone-Releasing Hormone (GHRH). Unlike its “With DAC” counterpart, this peptide lacks the Drug Affinity Complex, resulting in a significantly shorter half-life (approximately 30 minutes) that mimics the body’s natural pulsatile release of growth hormone. This modification improves resistance to enzymatic cleavage by DPP-IV, making it a highly effective tool for researching physiological growth hormone secretion patterns without the continuous stimulation associated with long-acting analogues.

  • Pulsatile GH Secretion: Primary agent for studying natural, wave-like secretion of growth hormone rather than a steady-state bleed.

  • Sleep Physiology: Investigated for its potential to increase slow-wave sleep (SWS) via GHRH receptor activation.

  • Metabolic Research: Used in studies focusing on lipolysis (fat loss) and glucose metabolism in animal models.

  • Synergistic Studies: Frequently used in conjunction with GHRPs (like Ipamorelin or GHRP-6) to observe amplified GH release profiles.

  • Formulation: Lyophilized powder.

  • Storage: -20°C for powder, -80°C for reconstituted solution.

  • Reconstitution: Bacteriostatic water or sterile saline.

  • Purity: ≥99% (HPLC)

  • Grade: Research Grade

  • Appearance: White lyophilized powder

  • Solubility: Soluble in water

For Research Use Only. Not for human consumption. Researchers should note the distinct pharmacokinetic difference between this product and CJC-1295 With DAC. Due to its short half-life (~30 mins), research protocols often require multiple administrations to mimic physiological pulses. It is generally well-tolerated in test subjects, but potential side effects noted in literature include transient flushing (vasodilation) and injection site irritation.

  • Campbell, R. M., et al. (1991). ORG 2766 and GRF analogs: peptide mediators of physiological processes. Peptides, 12(6), 1361-1365.

  • Sato, M., et al. (1990). GRF analogs with increased biological potency and stability. Biochemical and Biophysical Research Communications, 167(1), 360-366.

  • Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. (Note: Comparison study often cited for both variants).

In stock

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.